for semaglutide, liraglutide and dulaglutide, no dose adjustment is generally required, but monitor in severe renal impairment, especially with gastrointestinal losses Pregnancy and breastfeeding: GLP-1 therapies are not recommended during pregnancy
Bng cch trung ha cc gc t do, glutathione gip bo v ln da khi lo ha sm v tc hi ca nh nng mt tri
Other emerging GLP-1 options include orforglipron , an oral small molecule agonist, and CagriSema , which combines cagrilintide with semaglutide
Patients taking tirzepatide may experience a spectrum of bowel-related changes, with diarrhea and constipation representing the most frequently reported alterations
This is standard technique for sealed vials and should be done routinely, not just when you encounter resistance
By enhancing insulin response and reducing glucose spikes, it may offer metabolic advantages for individuals with insulin resistance